Genome Editing/Genome Engineering Market Report 2026

The genome editing/genome engineering market size has grown rapidly in recent years. It will grow from $10.17 billion in 2025 to $12.15 billion in 2026 at a compound annual growth rate (CAGR) of 19.5%. The growth in the historic period can be attributed to discovery of genome editing techniques, early research applications, availability of molecular biology tools, growth of academic research funding, demand for disease modeling.

The genome editing/genome engineering market size is expected to see rapid growth in the next few years. It will grow to $24.53 billion in 2030 at a compound annual growth rate (CAGR) of 19.2%. The growth in the forecast period can be attributed to clinical translation of gene editing therapies, expansion of agricultural genomics, improved editing accuracy, ethical framework development, commercialization of genome editing services. Major trends in the forecast period include increasing adoption of crispr-based editing tools, expansion of genome editing in disease research, rising use of cell line engineering applications, growing demand for precision gene modification, increased academic and government research funding.

The growing level of research activity is expected to propel the expansion of the genome editing and genome engineering market in the coming years. Research activities involve systematic and organized efforts undertaken by individuals, teams, or institutions to collect, analyze, interpret, and generate new knowledge within a specific field. Genome editing and genome engineering have emerged as critical drivers of this increasing research momentum, significantly reshaping the scientific research landscape. These advanced technologies enable researchers to precisely modify and better understand the complex genetic architecture of organisms, offering exceptional accuracy and flexibility. For example, in July 2023, the National Institute of Neurological Disorders and Stroke, a US-based government research institute, reported that the National Institutes of Health awarded more than $140 million to support the acceleration of genome editing approaches from laboratory research to clinical application. As a result, the rise in research activities is driving growth in the genome editing and genome engineering market.

Key companies in the genome editing and genome engineering market are increasingly entering into strategic collaborations and partnerships to reinforce their market position. A strategic business partnership refers to a formal collaboration between two or more companies, typically established through contractual agreements to achieve shared objectives. For instance, in April 2024, Regeneron Pharmaceuticals, a US-based biopharmaceutical company focused on developing treatments for immunology, oncology, and genetic disorders, formed a collaboration with Mammoth Biosciences, a US-based biotechnology company founded by Jennifer Doudna that specializes in CRISPR-based gene editing technologies. Through this partnership, Regeneron plans to combine Mammoth’s ultra-small CRISPR platforms with its own delivery technologies to accelerate the development of in vivo gene editing therapies targeting tissues beyond the liver, thereby expanding its therapeutic pipeline and technological capabilities. Mammoth Biosciences is a US-based company that provides CRISPR-based genome editing systems, including proprietary small Cas enzymes, for therapeutic and diagnostic use.

In February 2023, Ensoma, a US-based genomic medicines company focused on developing in vivo cell therapies, completed the acquisition of Twelve Bio for an undisclosed sum. Through this acquisition, Ensoma intends to incorporate Twelve Bio’s next-generation CRISPR-Cas12a technology into its Engenious platform to strengthen genome engineering capabilities and speed up the development of in vivo genomic therapies, reinforcing its technological position within the genome editing market. Twelve Bio is a Denmark-based company that offers advanced CRISPR-Cas gene editing tools, with a specialization in Cas12a engineering for therapeutic applications.

Major companies operating in the genome editing/genome engineering market are Thermo Fisher Scientific Inc., Merck Group, Genscript Biotech Corp, Sangamo Therapeutics Inc., Lonza Group AG, Editas Medicine Inc., CRISPR Therapeutics AG, Agilent Technologies Inc., Intellia Therapeutics, bluebird bio Inc., Transposagen Biopharmaceuticals Inc., Tecan Trading AG, Precision BioSciences, PerkinElmer Inc., Cellectis S.A, Applied StemCell Inc., Bio-Rad Laboratories Inc., Bio-Techne, Creative Biogene, Cyagen Biosciences, Dharmacon Inc., Eurofins Genomics LLC, Evotec SE, GeneCopoeia Inc., Genewiz, Horizon Discovery Group PLC, Inscripta Inc., Integrated DNA Technologies Inc., MaxCyte Inc., New England Biolabs, Novartis International AG.

North America was the largest region in the gene editing/genome engineering market in 2025. Asia-Pacific is expected to be the fastest-growing region in the genome editing/genome engineering market report during the forecast period. The regions covered in the genome editing/genome engineering market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the genome editing/genome engineering market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the genome editing market by increasing costs of imported reagents, consumables, laboratory instruments, and genome editing kits. Biotechnology and pharmaceutical companies are most affected due to reliance on imported tools. These tariffs raise research costs by increasing expenses for experimental workflows, scale-up activities, and validation studies, potentially slowing innovation. However, they encourage domestic production of reagents and research equipment, fostering regional self-sufficiency and long-term resilience in genome editing research.

The genome editing/genome engineering market research report is one of a series of new reports that provides genome editing/genome engineering market statistics, including genome editing/genome engineering industry global market size, regional shares, competitors with a genome editing/genome engineering market share, detailed genome editing/genome engineering market segments, market trends and opportunities, and any further data you may need to thrive in the genome editing/genome engineering industry. This genome editing/genome engineering market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Genome editing is a method that allows scientists to modify the DNA of a wide range of organisms, including plants, bacteria, and animals. Using genome editing technologies, researchers can change DNA sequences, thereby altering physical traits such as eye color or influencing the risk of developing certain diseases. Genome editing is commonly applied in research laboratories using animal models and cell systems to study disease mechanisms.

The primary product and service categories within genome editing and genome engineering include reagents and consumables, software and systems, and services. Reagents and consumables are applied at precise locations within the genome of a target organism to induce breaks, repairs, or mismatches through natural cellular mechanisms, resulting in specific changes to the DNA sequence. Consumables are materials that are used until depleted and then discarded, while reagents are compounds or substances that accelerate or enable chemical reactions. The technologies employed include Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR), Transcription Activator-Like Effector Nuclease (TALEN), Zinc Finger Nucleases (ZFN), antisense, and other approaches. These technologies are utilized in applications such as cell line engineering, genetic engineering, diagnostic uses, drug discovery and development, and other areas, and are adopted by biotechnology companies, pharmaceutical companies, and academic and government research institutions.

The genome editing/genome engineering market includes revenues earned by entities through cell line engineering, animal genetic engineering, and plant genetic engineering. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.